BSW Wealth Partners Raises Holdings in IQVIA Holdings Inc. $IQV

BSW Wealth Partners boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 28.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,981 shares of the medical research company’s stock after acquiring an additional 441 shares during the quarter. BSW Wealth Partners’ holdings in IQVIA were worth $312,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Clal Insurance Enterprises Holdings Ltd grew its stake in shares of IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after purchasing an additional 131 shares during the period. Golden State Wealth Management LLC grew its position in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after buying an additional 130 shares during the period. AllSquare Wealth Management LLC purchased a new position in IQVIA in the first quarter valued at $33,000. ST Germain D J Co. Inc. raised its position in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares during the period. Finally, Larson Financial Group LLC boosted its stake in shares of IQVIA by 109.9% during the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock worth $48,000 after acquiring an additional 144 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.2%

Shares of IQV stock opened at $204.25 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $237.34. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The stock’s fifty day moving average is $187.74 and its two-hundred day moving average is $167.57. The firm has a market capitalization of $34.72 billion, a P/E ratio of 29.56, a PEG ratio of 2.24 and a beta of 1.32.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on IQV. Mizuho lifted their price target on IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Redburn Partners set a $214.00 price objective on IQVIA in a research report on Wednesday, September 3rd. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. Finally, Cowen reaffirmed a “buy” rating on shares of IQVIA in a report on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $230.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.